JMB-HEADER NAUKA RAS RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2014  0,718
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 51(2017) N 2 p. 237-250; DOI 10.1134/S0026893317020145 Full Text

S.V. Kulemzin1, V.V. Kuznetsova1, M. Mamonkin2, A.V. Taranin1,3, A.A. Gorchakov1,3*

CAR T-cell therapy: Balance of efficacy and safety

1Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090 Russia
2Center for Cell and Gene Therapy, Baylor College of Medicine Texas Children's Hospital and Houston Methodist Hospital, Houston, USA
3Novosibirsk State University, Novosibirsk, 630090 Russia

*gorchakov@mcb.nsc.ru
Received - 2016-08-22; Accepted - 2016-10-12

Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.

chimeric antigen receptor, T-cells, cancer, adoptive immunotherapy



JMB-FOOTER RAS-JOURNALS